Moneycontrol PRO
HomeNewsBusinessSanofi gets CDSCO nod for Beyfortus India

Sanofi gets CDSCO nod for Beyfortus India

Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.

August 01, 2024 / 13:43 IST
Sanofi gets CDSCO nod for Beyfortus India

Sanofi gets CDSCO nod for Beyfortus India

Sanofi India on Thursday said it has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in India.

Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.

It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.

RSV is a highly contagious virus that can lead to serious respiratory illness in infants.

"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.

In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.

Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues.

PTI
first published: Aug 1, 2024 01:43 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347